Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.

American journal of physiology. Lung cellular and molecular physiology - 1 May 2007

Reynolds Ann M, Xia Wei, Holmes Mark D, Hodge Sandra J, Danilov Sergei, Curiel David T, Morrell Nicholas W, Reynolds Paul N

Abstract excerpt

Idiopathic pulmonary arterial hypertension (PAH) is characterized by proliferation of pulmonary vascular endothelial and smooth muscle cells causing increased vascular resistance and right heart failure. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are believed to cause the familial form of the disease. Reduced expression of BMPR2 is also noted in secondary PAH. Recent advances in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Morphogenetic Protein Receptors, Type II
Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endothelium, Vascular

Share to Hypertension, Pulmonary

Share to Hypoxia

Share to Muscle, Smooth, Vascular

Share to Proliferating Cell Nuclear Antigen

Share to Pulmonary Artery

Source

Identifiers

PMID: 17277049
DOI: 10.1152/ajplung.00020.2006

Genes

BMPR2
PAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.PMID 17277049Read ↗

Novel Advances in Modifying BMPR2 Signaling in PAHSemantic proximity Read ↗

BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.Semantic proximity Read ↗

Targeted gene delivery of <i>BMPR2</i> attenuates pulmonary hypertensionSemantic proximity Read ↗

Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.Semantic proximity Read ↗

Significance of BMPR2 mutations in pulmonary arterial hypertension.Semantic proximity Read ↗

BMP type II receptor as a therapeutic target in pulmonary arterial hypertensionSemantic proximity Read ↗

Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?Semantic proximity Read ↗

Molecular pathogenesis of pulmonary arterial hypertension.Semantic proximity Read ↗

Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.Semantic proximity Read ↗

Physiologic and molecular consequences of endothelial Bmpr2 mutation.Semantic proximity Read ↗

The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the PatientSemantic proximity Read ↗

Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.